News

• November 10, 2022
  Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement
• November 3, 2022
  Targovax ASA: Third quarter 2022 results
• October 26, 2022
  Invitation to Targovax’s third quarter 2022 presentation, Thursday 3 November
• October 20, 2022
  The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research – with updated publication info

All news

Company presentations

• Company presentation November 2022

Events

• February 16, 2023 Q4 Report Add to Calendar

All events

Mesothelioma 30-month data

The 30-month data from the mesothelioma trial was released December 2021. See press release here.
For a video presentation of the 24-month data from June 2021, please see links below:

• English
• Norwegian

Q3 interim report 2022

Targovax ASA (OSE: TRVX) announced its third quarter 2022 results on Thursday 3 November 2022. Targovax’s management will present the results at a live streamed webcast at 10:00 am CET to investors, analysts and the press. 

• Report
• Presentation
• Webcast

Read the report

Webcast presentation on Xtrainvestor

For a company presentation in Norwegian, please see video below.

• Webcast

Share price